Glenmede Trust’s Soleno Therapeutics SLNO Stock Holding History

Glenmede Trust’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-8,229	Closed	-$276K	–	1561
2026 Q1	$276K	Buy	8,229 +440	+6%	+$17.3K	﹤0.01%	1191
2025 Q4	$361K	Buy	+7,789	New	+$427K	﹤0.01%	1065
2025 Q1	$265K	Buy	+3,711	New	+$181K	﹤0.01%	1129

Glenmede Trust's SLNO Position: Q2 2026 in Review

Glenmede Trust sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 8,229 shares — an estimated $276K sold.

Glenmede Trust first reported a position in SLNO in Q1 2025 and held it in 3 quarters. The position peaked at $361K in Q4 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Glenmede Trust reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Glenmede Trust sold 8,229 Soleno Therapeutics shares in Q2 2026, an estimated $276K.
Glenmede Trust first reported a position in Soleno Therapeutics in Q1 2025 and held it in 3 quarters.
Glenmede Trust's Soleno Therapeutics position peaked at $361K in Q4 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Glenmede Trust's 13F filing for Q2 2026, filed 10 Aug 2026.